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Objective. To report one case of seizure following administration of oﬂoxacin. Case Summary. A 38-year-old woman with alcohol
dependence but no prior history of seizure disorder admitted in our inpatient alcohol detoxiﬁcation program was prescribed
oﬂoxacin four days after admission for a lower urinary tract infection. She was currently prescribed diazepam 30mg per day.
This treatment was continued without modiﬁcation following admission. Forty eight hours after starting oﬂoxacin and after
receiving ﬁve doses of oral oﬂoxacin, the patient experienced a seizure. Oﬂoxacin treatment was stopped and no further seizures
occurred. Neurological examination of the patient, laboratory tests, computerized tomography with contrast enhancement and
electroencephalography did not detect any abnormalities. Up to the last consultation, six months after admission, the patient has
reported no recurrence of the seizure. Discussion. Quinolone antibiotics vary in their ability to induce seizures, with oﬂoxacin
having one of the least potentials. In the present case, the seizure could be attributed in all probability to taking oﬂoxacin; since
she had no previous history of seizures, she did not present an alcohol withdrawal syndrome, benzodiazepine treatment was
not modiﬁed, the seizure occurred 48h after taking oﬂoxacin, but seven days after stopping drinking, no alternative aetiologies
for the seizure could be identiﬁed and no seizure recurrence was reported over the following seven months. Of reported cases
of seizures in patients treated with ﬂuoroquinolones, none concerned patients with alcohol dependence or patients treated
with benzodiazepines. Conclusions. The present case alerts us to the possibility that seizures may occur in alcohol dependent
patients treated with benzodiazepines who concomitantly prescribed a ﬂuoroquinolone. These widely-used antibiotics should
thus be prescribed with caution to patients undergoing detoxiﬁcation for alcohol dependence, particularly if they are also taking
benzodiazepines, irrespective of whether they have a previous history of seizures or not.
Copyright © 2009 Pierre Lahmek et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The ﬂuoroquinolones are a widely-used class of broad-
spectrum antibiotics, particularly useful for the treatment of
urinarytractinfectionscausedbygram-negativebacteria[1].
Eﬀects of ﬂuoroquinolones on the central nervous system
havebeen reported rarely,andarenon-speciﬁc.In particular,
seizures are extremely rare. These have been attributed to a
speciﬁc interaction of ﬂuoroquinolones with inhibitory γ-
aminobutyric acid (GABA) receptors on neurones, result-
ing in a reduction in the seizure threshold [2]. Alcohol
dependence is a risk factor for seizures, in particular in
individuals who present symptoms of alcohol withdrawal
[3, 4]. However, to our knowledge, seizures have not so far
been reported in alcohol-dependent patients treated with
ﬂuoroquinolones antibiotics whilst undergoing withdrawal.
This report describes a woman with alcohol dependence but
no prior history of epilepsy or seizures who experienced a
seizure after taking oﬂoxacin during medically-supervised
alcohol detoxiﬁcation.
2.CaseReport
A 38-year-old woman was admitted to our alcohol treatment
centre to undergo inpatient detoxiﬁcation. She presented
with a history of regular high alcohol consumption since the
ageof23,fulﬁllingdiagnosticcriteriaforalcoholdependence
(according to the DSM-IV) since the age of thirty. This was
her ﬁrst inpatient treatment for an alcohol-related problem.
Three years prior to admission, the patient reported a
previous period of abstinence following hospitalisation in2 Case Reports in Medicine
a psychiatric department for the treatment of a major
depressive episode. Her alcohol consumption had increased
dramatically since the last four months before admission and
she reported drinking between 50 and 75cl of whisky on
a daily basis (e.g., between 200 and 300 grams of ethanol
per day). Her last alcohol intake was the day prior to
hospitalisation and at admission her blood alcohol levels
were below the threshold of detection and she presented no
signs of a withdrawal syndrome according to the DSM-IV
(e.g., no increasing hand tremor, transient visual tactile or
auditory hallucinations, autonomic hyperactivity, insomnia,
nauseaorvomiting, psychomotoragitation,anxiety orgrand
mal seizure) at admission and during the next days. Thus no
supportive measure were needed.
Her medical history included a fracture of the right ankle
six years prior to admission, essential hypertension, allergic
asthma, anxiety and depression. No previous history of
seizures was reported. She was currently prescribed bisopro-
lol 10mg per day, venlafaxine LP 75mg bid, diazepam 30mg
per day, zolpidem 10mg per day, inhaled beclometasone
and salbutamol, and oral contraception with levonorgestrel.
These treatments were continued without modiﬁcation
following admission. Clinical examination revealed varicose
veins aﬀecting both legs and minor bruising to the back
and torso. No clinical signs suggestive of alcohol-related
pathology were detected. At admission, clinical examination
as well as routine hematology and biochemistry tests were all
normal, particularly potassium and sodium levels. Magne-
sium level was not measured.
Four days after admission, a lower urinary tract infection
was detected and Collibacillum identiﬁed as the pathogen
responsible.Forthisreason,treatmentwithoﬂoxacin200mg
bid was prescribed. No change was made to her other
medication. Forty eight hours after starting oﬂoxacin, six
days after admission and seven days after the last alcohol
intake, the patient experienced a generalised tonic-clonic
seizurelastingforﬁveminutesfollowedbyapost-ictalperiod
of twenty minutes. Clinical examination of the patient in
the hours following the episode only revealed a bilateral
facial haematoma around the eyes as a consequence of
the seizure and the fall. Neurological examination was
once again normal. Oﬂoxacin treatment was stopped and
no further seizures occurred. Laboratory tests performed
the next morning were normal (blood cell count, blood
chemistry, calcium, phosphorus, magnesium, blood glucose
and transaminases). Computerised tomography (CT) with
contrast enhancement and electroencephalography (EEG)
were performed and neither detected any abnormalities.
No further seizure occurred during the 21 days of hospi-
talisation. The patient still attends regular followup con-
sultations at our centre. Up to the last consultation, six
months after admission, she claims not to have consumed
any more alcohol and has reported no recurrence of the
seizure.
3. Discussion
This case depicts the occurrence of a generalised tonic-
clonic seizure in an alcohol dependent patient without
prior seizure history forty-eight hours after starting treat-
ment with oﬂoxacin. Seizures unrelated to epilepsy are
relatively common events, for example as complications of
deregulated metabolic states (hypoglycaemia, renal insuﬃ-
ciency, hyperglycaemia, dehydration, hyperhydration, hep-
atic insuﬃciency, or perturbations of calcium or phosphorus
homeostasis), as toxicological reactions (drug overdose or
withdrawal) or following infections of the central nervous
system (meningitis or encephalitis) [5, 6]. The seizures that
may occur following abrupt alcohol withdrawal fall into
this category of nonepileptic seizures, although they usually
are not suﬃciently severe to merit speciﬁc treatment or
management [3, 7, 8]. Postictal neurological examination is
usuallynormalinthesepatients.Ifwithdrawalseizuresoccur,
it is recommended to perform a basic physical and biological
examination, including EEG, CT or magnetic resonance
imaging, and laboratory tests appropriate to the individual
situation [9–11]. After a ﬁrst withdrawal seizure, anomalies
can be detected on the EEG in around 50% of cases and
on CT in between 35% to 55% of cases, whereas laboratory
tests are usually normal [10]. However, in the absence of
risk factors for repeated seizures, such as EEG anomalies or
other identiﬁed seizure aetiologies, only 25% of patients will
experience a second seizure in the two years following the
index episode [12].
Excessive alcohol consumption over prolonged periods
is toxic to the central nervous system and may lead to
structural and functional changes. From a functional per-
spective, ethanol inhibits neuronal excitability by facilitating
inhibitory GABAergic transmission. In alcohol dependence,
tolerance develops to this facilitatory action, involving
an increased sensitivity to the excitatory neurotransmitter
glutamate and reduced sensitivity to GABA. When alcohol
intake is abruptly ended, for example, during detoxiﬁcation,
this balance between excitation and inhibition is perturbed,
leading to a hyperexcitable state which manifests as the
alcoholwithdrawalsyndrome[3,4,7,13,14].Aroundhalfof
alcohol-dependent patients present a withdrawal syndrome
when they stop drinking, and seizures occur in around
ﬁve percent of cases. These are usually generalised tonic
clonic seizures occurring in eighty percent of cases between
eight hours and two days after stopping drinking [3, 4].
Benzodiazepines, notably diazepam, are the reference phar-
macological treatment for managing the alcohol withdrawal
syndrome [3, 4, 7, 14, 15], since they activate the GABAergic
system and this attenuate the hyperexcitable state.
In the present case, the seizure could be attributed in all
probability to taking oﬂoxacin, since she had no previous
history of seizures, she did not present an alcohol withdrawal
syndrome, benzodiazepine treatment was not modiﬁed, the
seizure occurred 48 hours after taking oﬂoxacin but seven
days after stopping drinking, no alternative aetiologies for
the seizure could be identiﬁed and no seizure recurrence
was reported over the following seven months. The pos-
sibility that the seizure was related to alcohol withdrawal
seemed low, given the absence of a withdrawal syndrome
or previous seizure history, and the time elapsed between
stopping drinking and the seizure. It is extremely rare for
alcohol withdrawal seizures to occur more than 72 hoursCase Reports in Medicine 3
following interruption of alcohol consumption [3, 4, 7].
Benzodiazepine withdrawal can also be excluded as the cause
of the seizure, since the dose of diazepam was not changed.
Following the criteria proposed by Naranjo et al. [16], it
can be concluded that the seizure was probably imputable
to oﬂoxacin. But this scale has been found to lack validity
and reliability regarding causality in various situations and
this would similarly be true for oﬂoxacin because oﬂoxacin
induced seizures are rare. Oﬂoxacin may well be the cause
attributable for the seizure. It is however impossible to
conclude deﬁnitely on the causal relationship from this case
report, considering the possible confounders, in this case
alcohol detoxiﬁcation.
The ﬂuoroquinolones are a generally well-tolerated
class of antibiotics. Outside the central nervous system,
the adverse drug reactions most frequently reported with
this treatment class are nausea and vomiting, hypo- or
hyper-glycaemia, increase in the QT interval, phototoxic-
ity, tendinopathy, and pseudomembranous colitis due to
Clostridium diﬃcile [17]. Adverse drug reactions involving
the central nervous system include dizziness, somnolence,
confusional states and tremor. The possible occurrence of
seizures after taking oﬂoxacin is a recognised potential
adverse reaction identiﬁed in the prescribing information
for this drug and indeed for all ﬂuoroquinolones antibiotics
[2, 17–19]. These seizures can be attributed either to the
binding of the antibiotic to the GABAA receptor or to
an interaction with excitatory amino acid receptors. In
both cases, these interactions would lead to a reduction in
seizure threshold [20]. It has been claimed that binding
to the GABAA receptor, and consequently seizure risk,
would be enhanced by certain substitutions at the 7-position
of the quinolone ring system, notably piperazine groups
as in ciproﬂoxacin [17, 21–23]. Consistent with this, we
have identiﬁed more than ten reported cases of seizures
associated with other 7-piperazinyl-ﬂuoroquinolones, such
as oﬂoxacin, levoﬂoxacin, enoxacin, and gatiﬂoxacine [2,
24–33], but also with non-piperazinylated, non-ﬂuorinated
quinolones such as nalidixic acid [34, 35]. The relative
convulsant potency of diﬀerent ﬂuoroquinolones has been
evaluated in vitro, and trovaﬂoxacine found to be the most
potent and levoﬂoxacin the least potent [2]. The factors that
determine convulsant potency are poorly understood, but
may include access to the central nervous system (which is
itselfrelatedtolipophilicity),aﬃnityfortheGABAA receptor
and activity at excitatory amino acid receptors [1, 2, 17–
19, 36–38].
When patients are treated with benzodiazepines, taking
other medication like oﬂoxacin that may interact with the
benzodiazepine-binding sites located on the same complex
as the GABA receptor site could increase the risk of seizures
[38]. It is possible that the case described here illustrates
such a phenomenon. The seizure could have been due to
displacement of GABA from its receptor, decreasing GABA-
ergic inhibition [2]. In contrast to this hypothesis, Akaike
et al. report that the inhibitory actions of ﬂuoroquinolones
combined with biphenyl acetic acid (the active metabolite
of the NSAID fenbufen, which potentiates the inhibitory
actions of ﬂuoroquinolones) on GABA-mediated responses
were not inﬂuenced by the presence of a benzodiazepine
antagonist (ﬂumazenil) indicating that their actions are
probablynotdirectlymediatedviathebenzodiazepinerecep-
tor [39]. Fluoroquinolone antibiotics should thus be used
with precaution in patients prescribed other drugs that may
also aﬀect the seizure threshold [17]. Interactions between
quinolones and certain non-steroidal anti-inﬂammatory
drugs or theophylline may also elicit seizures through such
a mechanism [20, 40, 41]. Of the seventeen reported cases
of seizures in patients treated with ﬂuoroquinolones, none
concerned patients with alcohol dependence or patients
treated with benzodiazepines [2, 21, 22, 24–35, 42]. In
half of these cases, another risk factor for seizures could
be identiﬁed, namely renal insuﬃciency, brain lesions,
disturbances of water or electrolyte homeostasis, or drug
overdose.Theintervalbetweentheﬁrstadministrationofthe
ﬂuoroquinolonesandtheseizurerangedbetweentwotofour
days,thatisbetweenthethirdandeighthdose,aswasalsothe
case for the patients described here.
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